Rua Life Sciences RUA.L · GBp

Its shares trade on LSE under the ticker RUA.L. It has been listed since 12 February 1997. In the fiscal year to 31 March 2026, it reported revenue of £4.5m and a net loss of £145,334.

RUA Life Sciences Plc is a holding company, which engages in the commercialization of biomedical polymer technology, components, and medical devices. The company is headquartered in Ayrshire, Ayrshire. The firm is focused on the commercialization of its biomedical polymer technology, components and medical devices. The firm has developed biostable, implantable polymers, including Elast-Eon and ECSil, which are long-term implantable co-polymers. Its Elast-Eon technology is available in a range of mechanical properties (Elastomers to rigid polymers), 70 Shore A to 80 Shore D. Its ECSil technology is available in a range of mechanical properties, but extends the softer materials to 70 Shore A. The firm has developed Elast-Eon and Reaction Injection Molding (RIM) technology for use in high-precision medical device components. Its polymers are developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae, stents and neuro stimulation devices.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Geoffrey BergIndependent Non-Executive Chairman of the Board, since 2024£40,600
• Mr. William BrownChief Executive Officer, since 2011£286,053
• Mr. Lachlan SmithChief Financial Officer, Executive Director, Company Secretary, since 2022£156,033
• Mr. John MckennaDirector of Marketing, Executive Director, since 2016£80,349
• Mr. Ian ArdillNon-Executive Independent Director£40,600
• Mr. John ElyNon-Executive Independent Director£41,354

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.